阿托伐他汀对老年急性冠脉综合征相关因子的影响

Influence of atorvastatin calcium tablets to acute senile coronary syndrone relative gactors

目的探讨阿托伐他汀对与急性冠脉综合征(ACS)相关的因子:C反应蛋白、白细胞介素-8、内皮素及血脂的影响,达到预防和治疗老年急性冠脉综合征的作用。方法将208例患者随机分成两组,一组为试验组,一组为对照组,两组均给予常规治疗,试验组在此基础上加用阿托伐他汀口服。同时选择一组健康组作为参照。并测定入院当日、半个月、3个月的血脂、C反应蛋白(CRP)、白细胞介素-8(IL-8)、内皮素(ET)及肝功、肾功的水平。结果阿托伐他汀对老年ACS患者血脂、CRP、白细胞介素-8(IL-8)、内皮素(ET)有很大的影响。试验组及对照组于入院当日查血脂、CRP、IL-8和ET均高于健康组(P<0.01),但两组间上述参数比较差异无显著性(P>0.05),至半个月时试验组的血脂、CRP、IL-8和ET均已明显下降,与健康组比较差异有显著性(P<0.05),至3个月时已降至正常。而对照组在半个月时CRP、IL-8和ET仍明显高于健康组(P<0.01～0.05),至3个月时,上述各项指标方降至接近正常水平(与健康组比较,P<0.05)。结论阿托伐他汀能降低老年ACS患者的CRP、IL-8和ET,可通过抑制巨噬细胞活性,从而抑制IL-8合成诱导,增强血小板活化,促进纤溶活化,并减少炎症反应;阿托伐他汀能降低老年ACS患者的血脂,改善内皮功能,减少心血管事件的发生。

[Objective] Discuss the influence of atorvastatin calcium tablets to acute senile coronary syndrome relative factors： c-reactive protein, interleukin-8, endothelial factor and blood fat, in order to prevent and cure acute senile coronary syndrome. [Method] 208 cases were randonly divided into two groups. One was test group, and the other was control group. The two groups were given routine treatment, and the test group was treated by atorvastatin calcium tablets, in the same time, we showed a health group as normal contols. We tested the level of blood fat, c- reactive protein, interleukin-8, hepatic and kidney function of all the patients on the first day, half month and the third month. [Result] Atorvastatin calcium tables had a significantly influence to the old patients, blood fat, CRP, IL-8, and ET. Before treatment, the level of blood fat CRP, IL-8, and ET of patients in both test gtoup and control group were higher than the health group （P 〈0.01）, and there was no significant difference between the two groups （P 〉0.05）. After half a month, the level of CRP, IL-8 and ET in test group decreased greatly, after three months, it decreased to normal level, but the level in control group was significantly higher than health group after half a month and decreased to normal level after three months. [Conclusion] Atorvastatin calcium tablets can decrease ACS patients＇ CRP, IL-8 and ET inhibit macrophage activity and IL-8 synthesis derivation, strengthen plastocyte activation, improve plasminogen activation and decrease inflammation. Atorvastatin calcium tablets can decrease ACS patients blood fat, improve endothelial function, and decrease the cardiovascular accident.